CollPlant Biotechnologies Ltd. (CPT.F)
| Previous close | 5.15 |
| Open | 5.50 |
| Bid | 5.35 x N/A |
| Ask | 5.90 x N/A |
| Day's range | 5.50 - 5.50 |
| 52-week range | 4.12 - 5.50 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 63.52M |
| Beta (5Y monthly) | 0.41 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen) for tissue regeneration and organ manufacturing, today announced financial results for the full year ended December 31, 2023 and provided a corporate update.
- PR Newswire
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 FULL YEAR FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION
CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen, today announced that it will report financial results for the full year of 2023 on Thursday, April 4, 2024, before the market open. The Company will then host a conference call and webcast to discuss its financial results and corporate updates on April 4th at 10:00 am Eastern Daylight Time.
- PR Newswire
CollPlant Issues Letter to Shareholders
CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and organ manufacturing, is pleased to issue the following letter from its Chief Executive Officer, Yehiel Tal.
